Shionogi links with Quark in osteoarthritis deal:
This article was originally published in Clinica
Executive Summary
US company Quark Biotech has linked in a research and licensing agreement with Shionogi of Japan to discover, identify, and determine the function of genes associated with osteoarthritis. Osaka-based Shionogi plans to develop and manufacture candidate diagnostic products for the disease using the information. It will have exclusive marketing rights in Japan and Asia to any products resulting from the deal. The company, whose main focus is pharmaceuticals, also expects to gain experience in discovery-related genomics and bioinformatics. The two companies will share co-marketing rights in the rest of the world. San Ramon, California-based Quark claims to have a comprehensive portfolio of genomic technologies and bioinformatics systems.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.